Cupid Limited reported a standalone net profit of ₹44.16 crore for the quarter ended June 30, 2026, marking a 194% year-on-year increase from ₹15.02 crore in Q1FY26. The surge in profitability was underpinned by a 159% rise in revenue from operations, which climbed to ₹154.72 crore from ₹59.80 crore in the corresponding period last year. EBITDA for the quarter stood at ₹600M, compared to ₹165M in Q1FY26, with the EBITDA margin expanding significantly to 38.80% from 27.56% year-on-year. This significant top-line and operational growth highlights robust demand across its portfolio of male and female condoms, water-based lubricants, and In Vitro Diagnostics (IVD) kits.

The Board of Directors approved the unaudited financial results on August 07, 2026, pursuant to Regulation 30 and Regulation 33 of the SEBI Listing Regulations. Statutory auditors Chaturvedi Sohan & Co., Chartered Accountants (FRN: 118424W), issued a limited review report with an unqualified opinion on both standalone and consolidated results. KPMSS & Associates was re-appointed as Cost Auditors for FY26-27 under Section 148 of the Companies Act, 2013.

Financial Performance Highlights

The following table summarises key standalone financial metrics for the quarter:

Operational profitability also saw a sharp improvement, with EBITDA rising to ₹600M from ₹165M in the year-ago period, driving the EBITDA margin to 38.80% versus 27.56% in Q1FY26. Consolidated net profit stood at ₹44.15 crore, compared to ₹15.01 crore in Q1FY26. Total comprehensive income was ₹1.71 crore, impacted by a ₹42.46 crore loss on equity instruments measured at fair value through Other Comprehensive Income (OCI). This valuation adjustment relates to the company's long-term strategic investment in Baazar Style Retail Limited, where fully convertible warrants are held for conversion into equity shares within 18 months.

Strategic Expansion and Governance

The Board granted in-principle approval for an exploratory exercise to evaluate a proposed business project in West Bengal. The initiative aims to assess land availability, infrastructure, and commercial feasibility for manufacturing medical devices and healthcare products. The project may be executed through Cupid Limited or a wholly owned subsidiary, subject to further approvals. Disclosures regarding this project will be made upon finalization, as per SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Additionally, the Board considered the continuation of Mr. Thallapaka Venkateswara Rao (DIN: 05273533) as a Non-Executive Independent Director post-attaining the age of 75 years, subject to shareholder approval via special resolution at the ensuing Annual General Meeting. The Directors' Report for FY26 and the notice for the 33rd AGM were also approved.

Cupid Limited has strengthened its strategic partnership with GII Healthcare Investment Limited through an additional follow-on investment of USD 5 Mn. The investment was funded entirely through internal accruals, signaling management's confidence in the long-term value creation potential of GII's healthcare platform. This move allows Cupid to increase its participation in the growth of the Gulf Cooperation Council (GCC) healthcare sector, which is supported by rising healthcare expenditure, expanding populations, and increased insurance penetration.

The investment follows an initial stake taken by Cupid in GII, a leading investment firm with assets under management exceeding USD 3.5 billion. GII operates across Saudi Arabia, the UAE, Europe, the USA, and India, with a track record of investing in high-quality healthcare assets. Notably, the platform holds a significant equity stake in Abeer Medical Company, one of Saudi Arabia's leading integrated healthcare providers, as well as AlMeswak Dental Company, a prominent dental and derma care chain in the Kingdom.

Strategic Rationale and Market Context

Management views the GCC healthcare sector as presenting compelling long-term growth opportunities, driven by sustained government investment and demographic shifts. By investing at an attractive valuation, Cupid aims to leverage these macroeconomic trends while diversifying its portfolio beyond its core domestic manufacturing business. The key parameters of the investment are summarised below:

Aditya Kumar Halwasiya, Chairman & Managing Director of Cupid Limited, stated that the decision reflects strong conviction in GII's strategy and the quality of underlying healthcare assets. He noted that the strategic relationship creates opportunities extending beyond financial returns, aligning with Cupid's mission to enhance preventive healthcare outcomes globally.

Operational Expansion and Portfolio Growth

While expanding its investment footprint, Cupid continues to scale its core manufacturing operations. The company completed a strategic land acquisition in Palava, Maharashtra, enabling a 1.5 times increase in production capacity. This expansion will augment annual output by approximately 770 million male barrier contraceptives and 75 million female barrier contraceptives.

Cupid remains a global leader in health and personal care products, including barrier contraceptives, water-based lubricants, and In Vitro Diagnostics (IVD) kits. The company has recently expanded into Fast-Moving Consumer Goods (FMCG), introducing fragrances, personal care items, and wellness solutions. It exports to over 125 countries and holds WHO/UNFPA pre-qualification for both male and female barrier contraceptives, a unique global distinction.

What the Numbers Show

The decision to fund the USD 5 Mn investment entirely through internal accruals indicates strong cash flow generation from Cupid's core operations. Rather than leveraging debt or diluting equity, the company is deploying existing liquidity to capture higher-growth opportunities in the GCC healthcare market. This approach preserves financial flexibility while positioning Cupid to benefit from the structural growth in international healthcare spending, particularly in Saudi Arabia where GII holds key stakes.